Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAD448
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Ophthalmic, Oral
01
Overview
SAD448 is a small molecule drug that acts as a peripherally restricted cannabinoid receptor type 1 (CB1) agonist. It was initially developed by Novartis for the potential treatment of ocular hypertension and chronic pain. Preclinical studies have shown that it can control spasticity in models of multiple sclerosis via action on peripheral nerve CB1 receptors while being excluded from the central nervous system (CNS), thereby reducing CNS-related side effects such as hypothermia. The drug has reached Phase I clinical trials for at least one indication[1][2][3][7][8].
- Other names
- SAD448SAD-448SAD 448581106-09-4951G84HQ4I
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on SAD448.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAD448.